EMBC — Stock Film
STOCK FILMSCENE 1/11EMBC · $4.94
Stock Expert AI presents
EMBC
Embecta Corp
~5 min film100% real numbersplain English
WHAT DOES THIS COMPANY DO?
Embecta Corp. What it actually does.

Develop and manufacture pen needles for insulin delivery. Produce syringes for administering insulin and other medications. Now — the numbers.

on the stock market since 2022
1,850 employees
$293.1M market value
WHERE DOES THE MONEY COME FROM?
80%Safety
SafetyManufacturing Facility 12%Product and Service, Other 8%
80% of all revenue comes from a single line: Safety.

That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.

Revenue last year:
$1.1B
The net profit left over:
$95.4M
Out of every $100 in sales, $9 stays as net profit.
THE SLICE THAT TURNS INTO PROFIT: 9%

This is an established company with proven profits.

Cash on hand:
$225.5M
Total debt:
$1.4B
The debt outweighs the cash.

The gap is $1.2B. In times of high interest rates, a gap like that can squeeze a company.

THE PRICE TAG
MARKET VALUE / ANNUAL PROFIT
3.1×

The market pays 3.1× for every dollar of annual profit — cheap, which is either an opportunity or a warning.

Against companies in its own sector, it looks cheaper than 94% of them.

Analysts' average target sits 1% above today's price.

INSIDE THE REPORT CARD

We compared this company with its own sector across five subjects.

A score of 50 means class average.

BUSINESS QUALITY
92
very strong

Profit power and business quality lead the class.

FINANCIAL STRENGTH
43
weak

Clearly below the class average.

VALUATION
94
very strong

The price looks reasonable next to what the company earns.

GROWTH
65
strong

This grade is a blend: the profit side is strong, the sales tempo slow.

PRICE MOMENTUM
39
weak

Clearly below the class average.

WORTH WATCHING

Price Momentum: The stock has lagged the market in recent months; investor interest is weak right now.

Financial Strength: The cash-and-debt balance is thin; the buffer for hard times is slim.

THE FIVE-YEAR JOURNEY
A long and steep decline.

An investor who bought at the very peak is down 89% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.

1
THE BRIGHT SIDE · 1/2
Executives are buying their own stock

Over the last 12 months, company executives reported 21 buys and 7 sells. Management buying with its own money is usually read as a good sign.

2
THE BRIGHT SIDE · 2/2
Pays a steady dividend

It pays out $0.32 per share each year — regular cash for whoever holds the stock.

1
THE RISKS · 1/3
Sales are shrinking

Over the last 4 years, sales fell about 2% a year on average. Profit is holding up, but a shrinking business is a risk worth watching.

2
THE RISKS · 2/3
The stock has lost its spark

Buyers haven’t stepped back in yet; the price hasn’t found its footing. Report-card grade: 39/100. For a turnaround signal, the stock first needs to close the gap with the market.

3
THE RISKS · 3/3
A thin financial cushion

The balance sheet offers little cushion against a rough stretch. Report-card grade: 43/100.

FINALE · THE GRADE
A
75 / 100 · MoonshotScore

On our five-subject report card, EMBC sits in the middle of the class: some subjects shine, others don’t. The grade moves as the numbers move.

The takeaway: EMBC is an established business that has proven its profits for years. The real debate isn’t the quality of the business — it’s what that quality should cost.

The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.

What would you like to do next?
Open the stock page →
This was a film — not investment advice.
Data: FMP & company filings
Sep 12, 2026 · stockexpertai.com · Stock Film